Company intelligence / Profile preview

Amdipharm Mercury

London, England, United Kingdom

Ownership: Private
Employees: ~200
Development stage: Other

Overview

AMCo offered a broad portfolio of niche, established medicines sold primarily as generic and off-patent products, including tablets, injectables, eye drops, and ointments, through commercial distribution channels spanning over 100 countries

Therapeutic areas: ImmunologyEndocrinologyRheumatologyOphthalmologyNephrologyMen's HealthInfectious DiseasesPulmonologyCardiovascularOtherNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Partnerships with multinational pharmaceutical companies for supply/distributionLEO Pharma (Fucithalmic acquisition)

Beyond the preview

Go deeper on Amdipharm Mercury.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amdipharm Mercury.

Explore the full profile